US backs COVID vaccines patent waiver at WTO after calls by India, South Africa
- The step is expected to clear the path for global availabilty of vaccines
- International Federation of Pharmaceutical Manufacturers and Associations opposed the decision
- Tai defined the step as an "extraordinary measure"
A global waiver on COVID-19 vaccine patents received the support of US President Joe Biden’s administration on Wednesday further clearing the path for global availability of the jabs. The United States vowed to negotiate for the notion at the World Trade Organisation meet.
However, the announcement faced a national backlash from the pharmaceutical sector of the country. The International Federation of Pharmaceutical Manufacturers and Associations called the decision “disappointing” and further added, “As we have consistently stated, a waiver is the simple but the wrong answer to what is a complex problem” in a statement, reported AFP.
The announcement was made by Katherine Tai, the US Trade Representative in the Biden adminstration. She said, “This is a global health crisis, and the extraordinary circumstances of the COVID-19 pandemic call for extraordinary measures” while highlighting the urgency of the matter.
Biden had been under intense pressure from world leaders to agree to waive protections for vaccine manufacturers in order to ramp up production and get the jabs out to more countries as rich nations have swept up the majority of the doses.
Tai said the United States will participate in the negotiations within the World Trade Organization but cautioned that discussions “will take time given the consensus-based nature of the institution and the complexity of the issues involved.”
Also Read: US lawmakers want Joe Biden to support waiver for India regarding COVID-19 intellectual property
The global trade body has for months been facing calls led by India and South Africa to temporarily remove the intellectual property protections on COVID-19 vaccines, in a move proponents say would help boost production in developing countries that so far have received far fewer jabs.
But that notion has until now met fierce opposition from pharmaceutical giants and their host countries, which insist the patents are not the main roadblocks to scaling up production, and warn the move could hamper innovation.
WTO chief Ngozi Okonjo-Iweala has been pressing for an international agreement to provide at least a temporary patent waiver.
“We need to have a sense of urgency on how we approach this issue of response to COVID-19 because the world is watching,” she said earlier Wednesday, describing equitable access to the tools to fight the pandemic as the “moral and economic issue of our time.”
Related Articles
ADVERTISEMENT